Product Description
Mechanisms of Action: CDK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eisai
Company Location:
Company CEO: Haruo Naito
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Colorectal Cancer|Adenocarcinoma|Renal Cell Carcinoma|Gastrointestinal Cancer|Breast Cancer|Melanoma|Myelodysplastic Syndrome|Preleukemia
Phase 1: Oncology Solid Tumor Unspecified|Gastrointestinal Cancer|Lung Cancer|Pancreatic Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00060567 |
E7070-A001-106 | P1 |
Completed |
Lung Cancer|Gastrointestinal Cancer|Pancreatic Cancer |
2013-03-01 |
2024-11-27 |
Primary Endpoints |
|
NCT00003976 |
EORTC-16973 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
None |
2019-03-21 |
||
NCT00003981 |
EORTC-16975 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
None |
2019-03-21 |
||
NCT01692197 |
NCI-2012-02065 | P2 |
Completed |
Myelodysplastic Syndrome|Preleukemia |
2017-06-07 |
2024-11-27 |
Primary Endpoints |
|
NCT00165594 |
E7070-J081-217 | P2 |
Terminated |
Gastrointestinal Cancer |
2006-07-01 |
2019-03-21 |
Treatments |
|
2004-002597-33 |
2004-002597-33 | P2 |
Completed |
Colorectal Cancer |
2006-01-10 |
2022-03-12 |
Treatments |
|
2004-000774-31 |
2004-000774-31 | P2 |
Completed |
Breast Cancer |
2005-06-24 |
2022-03-12 |
Treatments |
|
NCT00014625 |
Stage IV | P2 |
Completed |
Melanoma |
2001-11-01 |
2019-03-21 |
Treatments |
|
NCT00165854 |
E7070-E044-209 | P2 |
Completed |
Colorectal Cancer |
None |
2019-03-21 |
Treatments |
|
NCT00059735 |
E7070-A001-206 | P2 |
Completed |
Adenocarcinoma|Renal Cell Carcinoma |
None |
2019-03-21 |
Treatments |
|
NCT00165880 |
E7070-E044-213 | P2 |
Terminated |
Breast Cancer |
None |
2019-03-21 |
Treatments |
|
NCT00165867 |
E7070-E044-214 | P2 |
Completed |
Colorectal Cancer |
None |
2019-03-21 |
Treatments |
|
NCT00080197 |
E7070-A001-211 | P2 |
Completed |
Breast Cancer |
None |
2025-08-27 |
Primary Endpoints|Treatments |